Cancer

News on cancer research & diagnostics, liquid biopsy, and cancer risk testing.

The NGS-based test, which was approved by the FDA in June, will be now available to the insurers' members, who have non-small cell lung cancer, in four states.

BioSequence is looking to raise the profile of its genomic offering among clinicians, and to strengthen its case for reimbursement.

 

The NIH is aiming to fund projects evaluating the clinical potential of cancer biomarker assays that are already validated for research use.

The firm said that revenues for the third quarter is expected to be $63.1 million, which would be a 4 percent increase from the year-ago figure.

Participants shared data from head-to-head assay comparisons, reflected on the advancement of NGS and digital PCR methods, and discussed new standardization projects.